Is the analysis enough to get a deal over the line!!!
I guess the company had to make some sort of announcement but to be honest yes the trial shows safety WHICH IS POSITIVE but its not overly compelling based on a significant reduction in proteinuria in 3 out of 11 patients or 27% who had reached the mid point.
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX, page-39
-
- There are more pages in this discussion • 182 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
-0.020(4.60%) |
Mkt cap ! $228.5M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 43.5¢ | 41.0¢ | $731.5K | 1.748M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 269178 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 14070 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |